Return to homepagePandemic Pact

ImmunoCoV: Host immune responses to SARS-CoV-2: correlating kinetics with the natural history of infection

  • Funded by European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Total publications:2 publications

Grant number: RIA2020EF-3042

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $556,976

  • Funder

    European & Developing Countries Clinical Trials Partnership (EDCTP)

  • Principal Investigator

    Dr. Francis Ndungu

  • Research Location

    Kenya

  • Lead Research Institution

    African Research Collaboration for Health Ltd.

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The ImmunoCoV project (RIA2020EF-3042) aims to 1) test and validate antibody and other immunological assays for the diagnosis and further research on the immunology of SARS-CoV-2 infections in African populations, and 2) provide detailed kinetics of the immune response to SARS-CoV-2 in relation to viral shedding, clinical symptoms and asymptomatic infections.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Pre-COVID-19 ex vivo cross-reactive IFN-γ cellular response to SARS-CoV-2 spike overlapping peptides is more robust among Kenyan compared to Swedish adults

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.